Rekombinanter ITGAL (Efalizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter ITGAL (Efalizumab Biosimilar) Antikörper (ABIN5668044)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-CD11a [hu1124 (Efalizumab)], Human IgG1, kappa
-
Spezifität
- Binds to human LFA-1.
-
Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
Aufreinigung
- Protein A affinity purified
-
Reinheit
- > 98 % as determined by SDS-PAGE
-
Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
Immunogen
- Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes.
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
- Efalizumab binds to the LFA-1 alpha I domain blocking the ICAM-1 binding site via steric hindrance.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS with 0.02 % Proclin 300.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- ITGAL (Efalizumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Hintergrund
- LFA-1, integrin alpha L
-
UniProt
- P20701
Target
-